Kazakhstan vs Maldives: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Kazakhstan
0.2%
in 2024
Maldives
0.2%
in 2024
Kazakhstan rank
98th
Maldives rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Kazakhstan
- Maldives
How they compare
Kazakhstan currently reports 0.2% against 0.2% in Maldives, a difference of 0.0%.
Across all 10 years both countries report, Maldives has been ahead every year.
Kazakhstan ranks 98th and Maldives ranks 98th of 246 countries.
Maldives has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Kazakhstan | Maldives | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.4% | 0.2% | Maldives |
| 2020s | 0.2% | 0.2% | 0.0% | Maldives |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Kazakhstan or Maldives?
- Kazakhstan, at 0.2% against 0.2% in Maldives as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Kazakhstan and Maldives?
- 0.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Maldives?
- 10 years are reported by both, from 2015 to 2024.
- How do Kazakhstan and Maldives rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Kazakhstan ranks 98th and Maldives ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.